Details

Autor(en) / Beteiligte

• Zhang, Qian
• Pizzorno, Andrés
• Miorin, Lisa
• Bastard, Paul
• Gervais, Adrian
• Le Voyer, Tom
• Bizien, Lucy
• Manry, Jeremy
• Rosain, Jérémie
• Philippot, Quentin
• Goavec, Kelian
• Padey, Blandine
• Cupic, Anastasija
• Laurent, Emilie
• Saker, Kahina
• Vanker, Martti
• Särekannu, Karita
• García-Salum, Tamara
• Ferres, Marcela
• Le Corre, Nicole
• Sánchez-Céspedes, Javier
• Balsera-Manzanero, María
• Carratala, Jordi
• Retamar-Gentil, Pilar
• Abelenda-Alonso, Gabriela
• Valiente, Adoración
• Tiberghien, Pierre
• Zins, Marie
• Debette, Stéphanie
• Meyts, Isabelle
• Haerynck, Filomeen
• Castagnoli, Riccardo
• Notarangelo, Luigi D
• Gonzalez-Granado, Luis I
• Dominguez-Pinilla, Nerea
• Andreakos, Evangelos
• Triantafyllia, Vasiliki
• Rodríguez-Gallego, Carlos
• Solé-Violán, Jordi
• Ruiz-Hernandez, José Juan
• Rodríguez de Castro, Felipe
• Ferreres, José
• Briones, Marisa
• Wauters, Joost
• Vanderbeke, Lore
• Feys, Simon
• Kuo, Chen-Yen
• Lei, Wei-Te
• Ku, Cheng-Lung
• Tal, Galit
• Etzioni, Amos
• Hanna, Suhair
• Fournet, Thomas
• Casalegno, Jean-Sebastien
• Queromes, Gregory
• Argaud, Laurent
• Javouhey, Etienne
• Rosa-Calatrava, Manuel
• Cordero, Elisa
• Aydillo, Teresa
• Medina, Rafael A
• Kisand, Kai
• Puel, Anne
• Jouanguy, Emmanuelle
• Abel, Laurent
• Cobat, Aurélie
• Trouillet-Assant, Sophie
• García-Sastre, Adolfo
• Casanova, Jean-Laurent

Titel

Autoantibodies against type I IFNs in patients with critical influenza pneumonia

Ist Teil von

• The Journal of experimental medicine, 2022-11, Vol.219 (11)

Ort / Verlag

United States: Rockefeller University Press

Erscheinungsjahr

2022

Quelle

MEDLINE

Beschreibungen/Notizen

• Autoantibodies neutralizing type I interferons (IFNs) can underlie critical COVID-19 pneumonia and yellow fever vaccine disease. We report here on 13 patients harboring autoantibodies neutralizing IFN-α2 alone (five patients) or with IFN-ω (eight patients) from a cohort of 279 patients (4.7%) aged 6-73 yr with critical influenza pneumonia. Nine and four patients had antibodies neutralizing high and low concentrations, respectively, of IFN-α2, and six and two patients had antibodies neutralizing high and low concentrations, respectively, of IFN-ω. The patients' autoantibodies increased influenza A virus replication in both A549 cells and reconstituted human airway epithelia. The prevalence of these antibodies was significantly higher than that in the general population for patients <70 yr of age (5.7 vs. 1.1%, P = 2.2 × 10-5), but not >70 yr of age (3.1 vs. 4.4%, P = 0.68). The risk of critical influenza was highest in patients with antibodies neutralizing high concentrations of both IFN-α2 and IFN-ω (OR = 11.7, P = 1.3 × 10-5), especially those <70 yr old (OR = 139.9, P = 3.1 × 10-10). We also identified 10 patients in additional influenza patient cohorts. Autoantibodies neutralizing type I IFNs account for ∼5% of cases of life-threatening influenza pneumonia in patients <70 yr old.